Glyco-biomarker Immunoglobulin G (IgG) Detection Service

Glyco-biomarker Immunoglobulin G (IgG) Detection Service

Immunoglobulin G (IgG) is an essential antibody. CD BioGlyco has developed a variety of reliable strategies to provide clients with detection of blood IgG levels to reveal hyper-responsiveness to antigenic stimuli or physiological abnormalities at the site of IgG production, among other disorders.


IgG is a class of protein molecules that function as antibodies to help fight pathogens and protect the body from infections. The detection and quantification of human IgG levels are clinically important for allergy testing, assessing immune responses, and measuring the body's response to antigenic stimuli. And it can provide information about any physiological abnormalities at the site of IgG production and other neurological complications related to diseases such as CHIKV and multiple sclerosis. In addition, the detection of IgG also has an impact on the field of monoclonal antibodies (mAbs) for the treatment of cancer, autoimmune diseases and Alzheimer's disease.

The development of real-time, reliable and cost-effective technologies is significant to monitor treatment efficacy and improve patient care through personalized treatment protocols. Currently, IgG is quantified by techniques such as ELISA, fluorescence microscopy, immunoassays, mass spectrometry, liquid chromatography or cell-based assays. Routine analysis-based methods such as ELISA and cell-based immunofluorescence (IF) involve the use of a specific antigen to bind the IgG antibody followed by the detection of Ig biomarkers or Ig antigen complexes.

Overview of  surfactant hydrodynamic retardation effect detector (SHRED). (A) IgG molecular  structure. (B) Theory of operation. (C) Implementation of a protein detector. Fig.1 Overview of surfactant hydrodynamic retardation effect detector (SHRED). (A) IgG molecular structure. (B) Theory of operation. (C) Implementation of a protein detector. (Fatima, 2019)

Our Strategies

CD BioGlyco has developed various methods for providing the service of glyco-biomarker IgG detection for our clients. The strategies we provide include but are not limited to:

  • LC-MS is used to determine glycosylation changes in medium-abundance glycoproteins including IgG in patients' serum. Glycan separation by reversed-phase (RP)-LC, hydrophilic interaction chromatography (HILIC)-LC, and porous graphitized carbon (PGC)-LC is performed prior to MS detection.
  • HILIC-UPLC in combination with CE-LIF is used to characterize IgG-released N-glycans in human serum samples, and this strategy allowed rapid structural annotation of IgG N-glycans in a short time.
  • A novel sensor concept of the stagnant cap hydrodynamic delay detector (SHRED) is employed for label-free detection of IgG using its amphiphilic structure. This detection method is relatively simple, inexpensive, and real-time.


  • Application in assessing immunity to mumps, measles, rubella (MMR) and varicella
  • Application in the diagnosis of autoimmune hepatitis, food allergy, liver diseases, etc.
  • Application in monitoring disease progression

Advantages of Us

  • Reduce cost per sample analysis
  • Reproducibility and accurate results
  • High sensitivity and time-saving
  • Detailed after-sales service

With a world-class research platform and highly trained staff, CD BioGlyco has designed and validated multiple strategies for the rapid and sensitive detection of IgG. If you have a demand for glyco-biomarker detection services, please feel free to contact us.


  1. Fatima, A.; Basu, A. Label free quantitation of immunoglobulin G using the stagnant cap hydrodynamic retardation effect detector (SHRED). IEEE SENSORS. 2019, 1-4.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.